Zimmer upgraded to Strong Buy from Buy at Needham Needham upgraded Zimmer to Strong Buy citing accretion from the pending Biomet acquisition and its belief the recon market remains healthy. The firm has a $122 price target for shares.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Zimmer should be bought on any weakness from Q2 results, says RBC Capital RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.